&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-08-18, 19:05

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
Dora Legere

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-07-07, 18:00

Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-05-06, 16:00

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
Bradley Crotty

Popular Posts